The intricate architecture of the human brain, responsible for our thoughts, memories, and consciousness, relies on the precise functioning of its neuronal cells and the delicate balance of proteins that maintain their structure and communication. Among these vital components is tau, a protein that, under normal physiological conditions, acts as a crucial scaffold, stabilizing the internal framework of nerve cells known as microtubules. These microtubules are essential for preserving neuronal shape and facilitating the transport of vital molecules, thereby ensuring the efficient operation of brain circuits. However, in the context of debilitating neurodegenerative conditions such as Alzheimer’s disease and other tauopathies, tau undergoes a pathological transformation. It misfolds and aggregates into insoluble tangles, disrupting the very neuronal networks it was designed to support. These toxic formations interfere with synaptic function, impede neural communication, and ultimately contribute to the progressive cognitive decline and neuronal death characteristic of these diseases.
For decades, the scientific community has been intensely focused on understanding the mechanisms behind tau pathology, seeking therapeutic avenues to halt or reverse its destructive progression. A significant breakthrough in this ongoing endeavor was recently reported by researchers at Sanford Burnham Prebys, who identified a protein that appears to play a protective role against the damaging cascade initiated by abnormal tau. Published on July 17, 2026, in the esteemed journal Science Advances, this groundbreaking research illuminates the potential of bolstering a natural defense mechanism within the brain, offering a novel perspective for the development of future treatments targeting tau-related disorders.
The protein at the center of this discovery is known as SORLA, an acronym for sorting-related receptor with A-type repeats. While previous investigations, spanning the last fifteen to twenty years, had established SORLA’s capacity to mitigate the generation and accumulation of amyloid-beta, another hallmark protein implicated in Alzheimer’s disease, its specific involvement in the pathogenesis of tau tangles remained largely elusive. This knowledge gap presented a critical area for exploration, as Alzheimer’s disease is characterized by the simultaneous presence of both amyloid plaques and tau tangles, suggesting a complex interplay between these pathological entities. The Sanford Burnham Prebys team embarked on a mission to unravel SORLA’s influence on tau pathology, thereby broadening our understanding of its multifaceted role in neurodegenerative disease.
To rigorously investigate the protective capacity of SORLA, the researchers employed a sophisticated mouse model designed to mimic key aspects of human tauopathies. They meticulously crossbred mice engineered to express elevated levels of human SORLA with a strain of mice that naturally develop tau tangles, exhibit brain atrophy, and display cognitive impairments. This innovative genetic strategy allowed the scientists to directly assess whether an increased presence of SORLA could effectively counteract the formation of tau aggregates and the subsequent neurodegenerative damage. The experimental outcomes provided compelling evidence for SORLA’s protective effects. The study revealed that mice with higher SORLA concentrations exhibited a significant reduction in several key processes driving tau tangle formation and neurodegeneration. Specifically, SORLA was found to inhibit the aberrant addition of phosphate groups to tau proteins, a process termed hyperphosphorylation, which is a critical step in tau misfolding and aggregation. Furthermore, SORLA appeared to limit the propensity of these misformed tau proteins to act as "seeds" that initiate and propagate the formation of larger, more toxic tangles.
The beneficial impact of SORLA extended beyond its direct interaction with tau. The research indicated that elevated SORLA levels were associated with the maintenance of healthier synapses, the critical junctions where neurons communicate with each other. Moreover, these mice demonstrated a superior preservation of synaptic plasticity, the brain’s remarkable ability to adapt and modify its neural connections, a process fundamental for learning and memory. Huijie Huang, PhD, a staff scientist in the Huang lab at Sanford Burnham Prebys and the lead author of the study, expressed excitement over these findings, stating that upregulating SORLA could effectively suppress the detrimental effects observed in tauopathies, leading to reduced brain atrophy and less tau accumulation.
To further elucidate SORLA’s role, the research team also investigated the consequences of its absence. They examined mice genetically engineered to lack the Sorl1 gene, which provides the instructions for producing SORLA proteins. As anticipated, these animals exhibited the inverse of the protective effects observed in the high-SORLA group. The absence of SORLA exacerbated the harmful pathological changes associated with tauopathies, underscoring the protein’s vital protective function. Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys and senior and corresponding author of the manuscript, highlighted this crucial observation, noting that a deficiency in SORLA intensified the detrimental outcomes seen in tau-related brain disorders.
To pinpoint the underlying molecular mechanisms responsible for SORLA’s varied effects based on its abundance, the researchers employed advanced omics technologies, including single-cell sequencing and spatial mapping methods. These cutting-edge techniques allowed them to meticulously measure protein levels and gene activity within individual brain cells while simultaneously revealing the precise localization of RNA and proteins within the brain tissue. The comprehensive analysis revealed that increased SORLA expression effectively prevented detrimental alterations in protein production at the synapses. It also appeared to suppress several other biological pathways that are known to be activated during the progression of tauopathy.
Intriguingly, higher SORLA levels also demonstrated an impact on glial cells, the often-underappreciated support cells of the brain. These cells, including astrocytes and microglia, perform a multitude of essential functions, such as providing structural and metabolic support to neurons, maintaining the brain’s delicate internal environment, and orchestrating the inflammatory and repair responses to injury and disease. The study found that elevated SORLA levels mitigated disease-related patterns of gene activity within these glial cells, suggesting that SORLA may influence how these cells respond to neurodegenerative processes. One particularly noteworthy observation was the upregulation of a member of the plexin-B family of receptors in the absence of SORLA. This finding opens up new avenues for therapeutic intervention, as Huijie Huang pointed out, "There are unique drugs that can target this class of receptors that we may be able to apply to tau-related dementia disorders." This suggests a potential strategy of repurposing existing medications to modulate glial cell activity and possibly reverse some of the pathological features of tauopathies, a concept further elaborated by Timothy Huang as a potential future direction for research.
Building upon these compelling findings, the Sanford Burnham Prebys team plans to conduct further investigations to gain a more granular understanding of how different types of brain cells respond to fluctuations in SORLA levels. Their future research agenda includes implanting human neurons and glial cells into mouse brains. This approach will allow them to study the impact of various SORLA mutations within a living disease environment, providing a more accurate representation of human disease pathology compared to studies solely relying on mouse cells. Timothy Huang emphasized the importance of this translational step, stating that observing SORLA modulation and dysfunction within human cells in a diseased brain context would be significantly more informative for understanding human diseases.
Ultimately, this pioneering research into the protective role of SORLA holds significant promise for the development of novel therapeutic strategies. By clarifying the precise mechanisms through which SORLA shields the brain from toxic tau tangles, scientists may be able to devise ways to enhance this natural defense therapeutically. Furthermore, the study’s insights into the interplay between SORLA, tau pathology, and glial cell activation could lead to the identification of existing drugs that could be repurposed for the treatment of Alzheimer’s disease and other tau-driven dementias, offering a potentially faster path to clinical application. The collaborative effort involved contributions from researchers at Sanford Burnham Prebys, including Christina Huan Shi, Wenqi Yang, Juan C. Piña-Crespo, Jay Bhatnagar, Julian Curatolo, Rabi Murad, Palak Shah, Alex Campos, Alexandra Houser, Rebecca A. Porritt, Giau Van Vo, Tongmei Zhang, Shengjie Feng, and Kevin Y. Yip, as well as Qiang Xiao from The Scripps Research Institute. The study received vital support from the National Institutes of Health, the National Cancer Institute, and the National Institute on Aging, underscoring the broad scientific interest and investment in addressing neurodegenerative diseases.
About the Author
